JAZZ— Jazz Pharmaceuticals plc

MaterialsPharmaceuticals$16.7B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$245.7M-0.8%	$247.8M+154.8%	$97.3M+442.0%	$17.9M
Cost of product sales (excluding amortization of acquired developed technologies)	$503.3M+12.9%	$445.7M+2.3%	$435.6M-19.4%	$540.5M
Selling, general and administrative	$1.81B+30.6%	$1.39B+3.1%	$1.34B-5.2%	$1.42B
Research and development	$782.7M-11.5%	$884.0M+4.0%	$849.7M+43.9%	$590.5M
Intangible asset amortization	$654.7M+4.4%	$627.3M+3.1%	$608.3M+1.5%	$599.2M
Acquired in-process research and development	$947.9M+9378.6%	$10.0M-47.4%	$19.0M-95.7%	$444.1M
Total operating expenses	$4.70B+40.1%	$3.35B+3.0%	$3.26B-12.6%	$3.72B
Income (loss) from operations	-$430.2M-160.0%	$716.6M+23.9%	$578.6M+983.0%	-$65.5M
Interest expense, net	-$195.1M+18.1%	-$238.1M+17.7%	-$289.4M-0.4%	-$288.2M
Foreign exchange gain (loss)	-$2.6M+68.6%	-$8.2M-193.1%	$8.8M+146.2%	-$19.0M
Income (loss) before income tax benefit and equity in loss of investees	-$627.9M-233.5%	$470.4M+57.9%	$297.9M+179.9%	-$372.8M
Income tax benefit	-$272.4M-198.0%	-$91.4M+23.8%	-$119.9M+24.4%	-$158.6M
Equity in loss of investees	$732K-55.9%	$1.7M-44.8%	$3.0M-69.7%	$9.9M
Net income (loss)	-$356.1M-163.6%	$560.1M+35.0%	$414.8M+285.1%	-$224.1M
Basic (in dollars per share)	-$5840.00-164.5%	$9060.00+38.3%	$6550.00+283.0%	-$3580.00
Diluted (in dollars per share)	-$5840.00-167.5%	$8650.00+41.8%	$6100.00+270.4%	-$3580.00
Weighted-average ordinary shares used in per share calculations - basic (in shares)	$60981000.00-1.4%	$61838000.00-2.3%	$63291000.00+1.2%	$62539000.00
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	$60981000.00-7.6%	$66007000.00-8.4%	$72066000.00+15.2%	$62539000.00
Product sales, net
Royalties and contract revenues

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.